Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization.
TACE-refractory
drug-eluting bead
microsphere
post-embolization syndrome
tyrosine kinase inhibitor
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
07
2020
accepted:
03
09
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
To evaluate the potential of drug-eluting bead (DEB)-transcatheter arterial chemoembolization (TACE) as a treatment option for patients with refractory to conventional lipiodol-based TACE (c-TACE) especially with decreased liver function. We retrospectively evaluated the treatment results of DEB-TACE for 89 HCC nodules in 27 patients with c-TACE refractory according to liver function. Although overall survival was significantly better in Child-Pugh A patients than in Child-Pugh B patients (median survival time, MST: 561 vs 347 days, DEB-TACE could be a therapeutic option for advanced HCC patients with c-TACE refractory and decreased liver function.
Identifiants
pubmed: 33117752
doi: 10.2147/JHC.S273929
pii: 273929
pmc: PMC7569043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
181-189Informations de copyright
© 2020 Kobayashi et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Gut. 2020 Aug;69(8):1492-1501
pubmed: 31801872
Liver Cancer. 2014 Oct;3(3-4):458-68
pubmed: 26280007
J Hepatocell Carcinoma. 2019 Jun 17;6:93-103
pubmed: 31355158
Onco Targets Ther. 2019 Mar 26;12:2205-2214
pubmed: 30988625
J Vasc Interv Radiol. 2015 Jul;26(7):1067-1075.e3
pubmed: 25952641
Jpn J Radiol. 2012 Aug;30(7):560-6
pubmed: 22644412
Liver Cancer. 2017 Nov;6(4):325-336
pubmed: 29234636
Dig Dis. 2015 Oct;33(6):751-8
pubmed: 26488473
J Hepatocell Carcinoma. 2019 Jul 11;6:105-117
pubmed: 31372364
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Oncology. 2014;87 Suppl 1:32-6
pubmed: 25427731
Dig Liver Dis. 2016 Jun;48(6):571-7
pubmed: 26965785
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Medicine (Baltimore). 2019 May;98(21):e15314
pubmed: 31124925
Cardiovasc Intervent Radiol. 2020 Jan;43(1):55-64
pubmed: 31646378
Dig Dis. 2017;35(6):583-588
pubmed: 29040991
J Hepatol. 2012 Apr;56(4):886-92
pubmed: 22173160
Oncology. 2014;87(6):330-41
pubmed: 25227534
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Liver Cancer. 2018 Mar;7(1):1-19
pubmed: 29662829
Dig Dis. 2017;35(6):602-610
pubmed: 29040999
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):75-85
pubmed: 27350573
Liver Cancer. 2019 Mar;8(2):121-129
pubmed: 31019902
Hepatology. 2002 May;35(5):1164-71
pubmed: 11981766
Clin Transl Oncol. 2019 Feb;21(2):167-177
pubmed: 30003530
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Gut Liver. 2013 Jan;7(1):89-95
pubmed: 23424047
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Korean J Radiol. 2015 Jan-Feb;16(1):125-32
pubmed: 25598680
J Vasc Interv Radiol. 2019 Aug;30(8):1303-1309
pubmed: 31155500
Liver Cancer. 2015 Dec;4(4):253-62
pubmed: 26734579
Hepatol Res. 2015 Jan;45(2):190-200
pubmed: 25388603
Gastroenterology. 2006 Aug;131(2):461-9
pubmed: 16890600
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52
pubmed: 19908093
Br J Cancer. 2014 Jul 15;111(2):255-64
pubmed: 24937669